

# Annular elastolytic giant cell granuloma after COVID-19 vaccination

Viviana Lora,<sup>1\*</sup> Arianna Lamberti,<sup>2,3\*</sup> Monia Di Prete,<sup>2</sup> Dario Graceffa,<sup>1</sup> Carlo Cota<sup>2</sup>

<sup>1</sup>Dermatology Unit, San Gallicano Dermatological Institute, IRCCS, Rome; <sup>2</sup>Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Rome; <sup>3</sup>Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy

\*These authors have equally contributed to the work.

## Abstract

The pandemic of SARS-CoV-2 during the first years of the 2020s led to a great commitment to develop effective vaccines. Despite the good safety and tolerability profile, vaccines may trigger a broad spectrum of cutaneous side effects. Granulomatous dermatitis has been rarely reported after SARS-CoV-2 mRNA

vaccines, but no cases of annular elastolytic giant cell granuloma have been described. Moreover, in our case, it was also associated with a central area of mid-dermal elastolysis, confirming the strong association between these two diseases already reported in the literature. The observation of occasional eosinophils within the infiltrate and the presentation of the cutaneous eruption a few days after the administration of the second dose of the Pfizer/BioNTech (BNT162b2) vaccine are highly suggestive of a drug-related eruption. To our knowledge, this is the first report in the literature of an annular elastolytic giant cell granuloma as an adverse effect of the SARS-CoV-2 vaccination.

Correspondence: Carlo Cota, Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, Via Elio Chianesi, 53, 00144 Rome, Italy.

Tel.: +39 06 5266 5367 - Fax: +39 06 5266 5226.

E-mail: carlo.cota@ifo.it

Key words: COVID-19 vaccination, elastic fibers, elastophagocytosis, granulomatous dermatitis, mid-dermal elastolysis.

Contributions: all authors substantially contributed to the conception of the work and the analysis and interpretation of data for the work. All authors drafted the work, reviewed it critically for important intellectual content and approved the final version to be published. All authors agreed to be accounted for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: not required. The study has been conducted in accordance with the Helsinki Declaration.

Patient consent for publication: the patient signed a written informed consent to publication.

Funding: none.

Availability of data and materials: available upon reasonable request to the corresponding author.

Received: 28 July 2023.

Accepted: 23 August 2023.

Early view: 12 September 2023.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

Dermatology Reports 2024; 16:9811

doi:10.4081/dr.2023.9811

*Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*

## Introduction

The global spread of COVID-19 during the first years of the 2020s led to a great commitment to vaccine development to reach herd immunity and reduce morbidity and mortality.<sup>1</sup> Two mRNA vaccines, produced by Pfizer-BioNTech and Moderna, received emergency use authorization from the US Food and Drug Administration in December 2020, and subsequently from the European Medicines Agency, recommending them for individuals aged  $\geq 12$  and  $\geq 18$  years, respectively.<sup>2,3</sup> Although these vaccines display a good safety and tolerability profile, it has been widely reported in the literature that they may trigger a broad spectrum of cutaneous side effects, rarely with severe prognosis.<sup>4,5</sup>


## Case Report

A 75-year-old woman came in January 2022 for the appearance of a broad asymptomatic V-shaped dermatosis, covering most of the trunk, with an erythematous raised centrifugal border, consisting of numerous confluent annular macules and papules, surrounding a pale atrophic center (Figure 1 A-C). The disease occurred a few days after the second dose of Pfizer/BioNTech (BNT162b2) vaccine administration and worsened after the third. She was otherwise healthy; no personal or familial history of dermatological or autoimmune diseases emerged. Laboratory tests and total body computed tomography were unaffected.

Two skin biopsies were obtained from the edge and the atrophic center of the lesion, respectively. The first specimen revealed the presence, at various levels of the dermis, of a granulomatous inflammatory infiltrate with multinucleated giant cells exhibiting elastophagocytosis. In some areas, in the proximity to the granulomas, numbers of mononuclear cells and occasional eosinophilic granulocytes were also noted (Figure 2). In the second biopsy, a scanty perivascular lymphohistiocytic infiltrate was observed in the upper dermis with few multinucleated giant cells showing elastophagocytosis in the mid-reticular dermis. Orcein staining better showed a well-demarcated band-like elastolysis in the mid and upper reticular dermis, with clear reduction or com-



**Figure 1.** Clinical images of elastolytic granulomatous dermatitis associated with Pfizer/BioNTech (BNT162b2) vaccine. **A,B**) A broad V-shaped dermatosis of the chest and the back; **C**) a detail of the slightly raising erythematous border consisting of annular macules and papules with a tendency to coalesce, surrounding a pale atrophic center. **D**) after two months of methotrexate therapy, the rash appears reduced in size, less infiltrated and less erythematous.



**Figure 2.** **A**) Histopathological images of the punch biopsy from the erythematous infiltrated border of the lesion, showing a granulomatous reaction pattern (original magnification 25 $\times$ ); **B**) the dermal inflammatory infiltrate is composed mostly by multinucleated giant cells, associated with small aggregates of lymphocytes (original magnification 100 $\times$ ); **C**) At higher magnification, occasional eosinophils are present within the infiltrate (original magnification 200 $\times$ ); **D**) orcein stain reveals fragmented elastic fibers and elastophagocytosis (original magnification 200 $\times$ ).



plete loss of the elastic fibers, and the preservation of the elastic component of the papillary dermis, as occurs in the so-called mid-dermal elastolysis (Figure 3).

Therefore, according to clinical-pathological findings and considering the temporal proximity with the vaccine administration, we diagnosed her with annular elastolytic giant cell granuloma (AEGCG), evolving into mid-dermal elastolysis, associated with Pfizer/BioNTech vaccine. The patient did not improve significantly after one month of topical steroids, then she was switched to 10 mg/week methotrexate therapy with folic acid supplementation for two months, with evident benefit (Figure 1D).

## Discussion

The skin is commonly involved in a broad spectrum of vaccine-derived adverse events, ranging from local site reactions to generalized rashes.<sup>4</sup> Nowadays, granulomatous dermatitis has been rarely reported after SARS-CoV-2 mRNA vaccines, and, to our knowledge, no cases of AEGCG have been described.<sup>6</sup> AEGCG is a rare granulomatous disorder characterized by elastolysis and elastophagocytosis. Etiopathogenesis is still controversial: environment, neoplasm, infections, and autoimmune disorders may trigger the process by modifying the antigenicity of elastic fibers and precipitating cellular immunological reactions.<sup>7,8</sup>


In this context, different hypotheses may explain the elastic tissue damage. The immune response induced by SARS-CoV-2

mRNA vaccines, based on neutralizing antibody development by the expression of SARS-CoV-2 spike protein, determines pleiotropic effects on the host cells. Vaccine-induced T-cell activation and release of TNF- $\alpha$  and IFN- $\gamma$  cause an exaggerated immune response that, in certain vulnerable settings, could initiate hyper-inflammatory changes and increase cytokine release with subsequent macrophage activation.<sup>4</sup> The macrophage-mediated inflammatory events imply the release of destructive enzymes and cytokines against various components of the extracellular matrix, *i.e.*, towards the elastic fibers in the case here reported. Damaged elastic fibers and intense macrophage activation could explain the development of the granulomatous inflammatory process.<sup>9</sup>

Further supposed pathogenic mechanisms could be represented by molecular mimicry and crossed immune reactivity between antibodies against SARS-CoV-2 spike glycoprotein and host peptide protein, such as elastic tissue.<sup>9</sup>

Cota *et al.* supported the autoimmune hypothesis of mid-dermal elastolysis, recognizing the role of increasing susceptibility to develop local and/or systemic autoimmune conditions to an inflammatory environment and to the loss of immune self-tolerance to tissue-associated antigens.<sup>10</sup>

The presence of eosinophils in the inflammatory infiltrate accompanying a cutaneous eruption has long been considered a histopathological clue for differentiating drug eruptions from other diseases presenting with lichenoid and/or perivascular lymphocytic infiltrates in the superficial dermis, such as viral exanthema. At least isolated eosinophils are reported in 2/3 of cases of



**Figure 3.** A) Histopathological images of the punch biopsy from the atrophic center of the lesion, showing a mild superficial perivascular inflammatory infiltrate (original magnification 25 $\times$ ); B) orcein stain demonstrates the absence of elastic fibers in the mid dermis, with their preservation in the papillary dermis and in the lower reticular dermis (original magnification 40 $\times$ ).

confirmed drug eruptions and, when present, are scattered within the lymphocytic infiltrate.<sup>11</sup> In our case, the observation of occasional eosinophils in association with the temporal criterion of the presentation of the cutaneous eruption a few days after the administration of the second dose of Pfizer/BioNTech (BNT162b2) vaccine is highly suggestive of a drug-related eruption.

Granulomatous features are classically present, both clinically and histopathologically, in the course of type IV cutaneous hypersensitivity reactions. An interesting paper by Magro *et al.* concerning the COVID-19 vaccine-induced cutaneous changes reported granulomatous features in 5/22 patients examined, with interstitial patterns in the majority of the cases; however, granulomatous vasculitis and folliculitis have also been observed.<sup>12</sup> Some of these reactions resembled classic cutaneous manifestations of mild COVID-19, leading to the consideration that a potential responsible for these vaccine-related reactions could be the novel protein manufactured. These considerations may be extended also to AEGCG, which is definitely a granulomatous disorder that may be triggered by factors modifying the antigenicity of elastic fibers, thus precipitating cellular immunological reactions.

---

## Conclusions

To our knowledge, AEGCG has not yet been reported in the literature as a side effect of SARS-CoV-2 vaccination. Its appearance after the second dose and its worsening after the third could be explained by the need to reach a sufficient antigenic title to stimulate an autoimmune response or to get an immunological memory. Therefore, AEGCG may represent a possible vaccine-derived adverse reaction.

---

## References

1. Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. *J Pharm Pract* 2022;35:947-51.
2. Wallace M, Woodworth KR, Gargano JW, et al. The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years - United States, May 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:749-52.
3. Wallace M, Moulia D, Blain AE, et al. The advisory committee on immunization practices' recommendation for use of Moderna COVID-19 vaccine in adults aged  $\geq 18$  years and considerations for extended intervals for administration of primary series doses of mRNA COVID-19 vaccines - United States, February 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:416-21.
4. Niebel D, Novak N, Wilhelmi J, et al. Cutaneous adverse reactions to COVID-19 vaccines: insights from an immunodermatological perspective. *Vaccines* 2021;9:944.
5. Lamberti A, Lora V, Graceffa D, et al. Nail psoriasis: a rare mRNA COVID-19 vaccine reaction. *J Eur Acad Dermatol Venereol* 2022;36:e745-6.
6. Nguyen TH, Gabros S, Friefeld S, et al. Generalized granuloma annulare after COVID-19 vaccination. *JAAD Case Rep* 2022;25:18-21.
7. Qian YT, Liu JW, Liu W, et al. A retrospective study of 105 patients with elastolytic giant cell granuloma and a proposal for a new clinical classification. *Acta Derm Venereol* 2022;102:adv00684.
8. Müller FB, Groth W. Annular elastolytic giant cell granuloma: a prodromal stage of mid-dermal elastolysis? *Br J Dermatol* 2007;156:1377-9.
9. Nunez-Castilla J, Stebliankin V, Baral P, et al. Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. *Viruses* 2022;14:1415.
10. Cota C, Latini A, Lora V, Cerroni L. Mid-dermal elastolysis as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected patient. *J Am Acad Dermatol* 2014;71:e134-5.
11. Ernst M, Giubellino A. Histopathologic features of maculopapular drug eruption. *Dermatopathology* 2022;9:111-21.
12. Magro C, Crowson AN, Franks L, et al. The histologic and molecular correlates of COVID-19 vaccine-induced changes in the skin. *Clin Dermatol* 2021;39:966-84.